ABSTRACT
INTRODUCTION
Maternal serum levels of pregnancy-associated plasma protein-A (PAPP-A) in the first trimester of pregnancy are decreased in pregnancies with fetal trisomies 21, 18 or 13 and in those with impaired placentation resulting in pre-eclampsia (PE) and delivery of small-for-gestational-age (SGA) neonates 1 -5 . There is also some evidence that serum PAPP-A is reduced in the second trimester in pregnancies that develop PE, but the levels are increased in cases with established disease 6 -9 . Maternal serum levels of free β-human chorionic gonadotropin (β-hCG) in the first trimester of pregnancy are increased in pregnancies with fetal trisomy 21 and decreased in trisomies 18 and 13 1, 2 . Serum free β-hCG is increased in pregnancies with established PE and in the third trimester before clinical onset of the disease, but is decreased or unaltered at 11-13 weeks' gestation 10 -14 . We have proposed that the best approach to screening for PE is to use Bayes' theorem to combine the a-priori risk from maternal characteristics and medical history with the measurement of biomarkers 15 -17 . Our approach assumes that, if the pregnancy was to continue indefinitely, all women would develop PE and whether they do so or not before a specified gestational age depends on competition between delivery before or after development of PE. The effect of maternal factors and biomarkers is to modify the mean of the distribution of gestational age at delivery with PE so that in pregnancies at low risk of PE the gestational-age distribution is shifted to the right with the implication that, in most pregnancies, delivery will actually occur before development of PE. In high-risk pregnancies, the distribution is shifted to the left and the smaller the mean gestational age the higher is the risk of PE. The objectives of this study were to present the distribution of serum PAPP-A and free β-hCG values at 11-13, 19-24 and 30-34 weeks' gestation in pregnancies that develop PE and examine the performance of screening for PE by serum PAPP-A and free β-hCG at these stages in pregnancy.
METHODS

Study population
The data for this study were derived from prospective screening for adverse obstetric outcomes in women attending three routine hospital visits at King's College Hospital (between March 2006 and July 2014), University College London Hospital (between April 2009 and July 2013), and Medway Maritime Hospital (between April 2010 and July 2014), UK. In the first visit, at 11 + 0 to 13 + 6 weeks' gestation, we recorded maternal characteristics and medical history and performed combined screening for aneuploidies 2 . The second visit, at 19 + 0 to 24 + 6 weeks' gestation, and the third at 30 + 0 to 34 + 6 weeks, included ultrasound examination of the fetal anatomy and estimation of fetal size. Gestational age was determined by the measurement of fetal crown-rump length at 11-13 weeks or fetal head circumference at 19-24 weeks 18, 19 .
Written informed consent was obtained from the women agreeing to participate in a study on adverse pregnancy outcome, which was approved by the ethics committee of each participating hospital. The inclusion criteria for this study were singleton pregnancy delivering phenotypically normal live birth or stillbirth at or after 24 weeks' gestation. Pregnancies with aneuploidy or major fetal abnormalities, and those ending in termination, miscarriage or fetal death before 24 weeks' gestation were excluded.
Patient characteristics
Patient characteristics included maternal age, racial origin (Caucasian, Afro-Caribbean, South Asian, East Asian and mixed), method of conception (spontaneous/assisted conception requiring the use of ovulation drugs/in-vitro fertilization), medical history of chronic hypertension, diabetes mellitus, systemic lupus erythematosus (SLE) or antiphospholipid syndrome (APS), family history of PE in the mother of the patient and obstetric history including parity (parous/nulliparous if no previous pregnancy at or after 24 weeks), previous pregnancy with PE, gestational age at delivery and interval in years between birth of the last child and estimated date of conception of the current pregnancy. Maternal height was measured in the first visit and maternal weight in each visit.
Measurement of maternal serum PAPP-A and free β-hCG
In the patients included in this study, maternal serum PAPP-A and free β-hCG were measured at each visit by automated biochemical analyzers within 10 min of blood sampling. The first-trimester samples were analyzed using the DELFIA Xpress system (PerkinElmer Life and Analytical Sciences, Waltham, MA, USA) and in the second and third trimesters the analysis was by the Cobas e411 system (Roche Diagnostics Ltd., Penzberg, Germany).
Outcome measures
Data on pregnancy outcome were collected from the hospital maternity records or the general medical practitioners of the women. The obstetric records of all women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was PE, as defined by the International Society for the Study of Hypertension in Pregnancy 20 . The outcome measures for this study were PE delivering < 32, at 32 + 0 to 36 + 6, < 37 and ≥ 37 weeks' gestation.
Statistical analysis
Competing-risks model
The distribution of gestational age at delivery with PE was defined by two components: first, the prior distribution based on maternal characteristics 15 and second, the distribution of serum PAPP-A and free β-hCG multiples of the median (MoM) values with gestational age at delivery in pregnancies affected by PE. The values of PAPP-A and free β-hCG were log 10 transformed to achieve homogeneity of variance and approximate Gaussian distributional form. Each measured value in the unaffected and PE pregnancies was expressed as a MoM, adjusting for those characteristics found to provide a substantive contribution to the log 10 -transformed value 21, 22 . Risks of PE were obtained by applying Bayes' theorem to derive the posterior distribution of gestational age at delivery with PE from the maternal factors specific prior distribution 15 and the likelihood function of PAPP-A and free β-hCG. The likelihood function comprises the regression of log 10 MoM PAPP-A and free β-hCG on gestational age at delivery with PE.
Model-based estimates of screening performance using Bayes' theorem
To provide model-based estimates of screening performance, the following procedure was adopted. First, we obtained the dataset of 123 406 singleton pregnancies with available data on maternal factors 15 . Second, for each of the records, PAPP-A and free β-hCG MoM values Table 2 Empirical and model-based detection rates of screening for pre-eclampsia (PE) by maternal factors and by a combination of maternal factors and serum pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-hCG) at 11 - were simulated from the fitted multivariate Gaussian distribution for log-transformed MoM values. Third, risks were obtained using the competing-risks model from the simulated MoM values and the pregnancy characteristics. These three steps were applied to the pregnancies within the normal group with no restriction on the time of delivery. Fourth, for a given false-positive rate (FPR), risks from the normal group were used to define a risk cut-off. The proportion of PE risks was then used to obtain an estimate of the associated detection rate (DR). The area under the receiver-operating characteristics curve was also calculated. The simulations were repeated 10 times to reduce variability due to the simulation process and provide suitably precise model-based estimates of performance.
Empirical performance of screening
Five-fold cross validation was used to assess the performance of screening for subgroups of PE according to gestational age at delivery, by models combining maternal factors with serum PAPP-A and free β-hCG. The data were divided into five equal subgroups, the model was then fitted five times to different combinations of four of the five subgroups and used to predict risk of PE in the remaining fifth of the data. In each case, the maternal-factor model and the regression models were fitted to the training dataset comprising four-fifths of the data and used to produce risks for the hold-out sample comprising the remaining fifth of the data. The statistical software package R was used for data analyses 23 and the survival package 24 was used for fitting the maternal-factors model.
RESULTS
The characteristics of the study population of singleton pregnancies with measurements of serum PAPP-A and free β-hCG are summarized in Table 1 .
The median PAPP-A MoM in unaffected pregnancies was 1.000 (95% CI, 0.996-1.004). In the PE group, PAPP-A MoM was decreased at 11-13 weeks (0.850 (95% CI, 0.830-0.870)), not significantly altered at 19-24 weeks (1.019 (95% CI, 0.997-1.040)) and increased at 30-34 weeks (1.236 (95% CI, 1.205-1.268)). The median β-hCG MoM in unaffected pregnancies was 1.000 (95% CI, 0.995-1.005). In the PE group, β-hCG MoM was not significantly altered at 11-13 weeks (1.014 (95% CI, 0.990-1.038)) and was increased at 19-24 weeks (1.288 (95% CI, 1.253-1.324)) and at 30-34 weeks (1.680 (95% CI, 1.621-1.742)).
The relationship of PAPP-A and free β-hCG MoM values with gestational age at delivery in pregnancies that developed PE is shown in Figure 1 and the regression equations are given in Table S1 . The standard deviation for log 10 PAPP-A and free β-hCG MoM in unaffected pregnancies and in those that developed PE are given in Table S2 .
Empirical and model-based performance of screening for PE by maternal factors and serum PAPP-A and free β-hCG are shown in Tables 2 and S3 . All model-based results were within the 95% CI of the empirical data. Combined screening with maternal factors and serum PAPP-A at 11-13 and 30-34 weeks and maternal factors and serum free β-hCG at 19-24 and 30-34 weeks improved the prediction of preterm PE provided by maternal factors alone.
DISCUSSION
Principal findings of the study
The findings of this study demonstrate that, in pregnancies that develop PE compared to unaffected pregnancies, maternal serum PAPP-A is decreased during the first trimester, is not significantly different in the second trimester and is increased in the early third trimester, and serum free β-hCG is not significantly different in the first trimester but is increased in the second and third trimesters, the deviation from normal increasing with increasing gestational age at screening. The separation in MoM values from normal is greater with an earlier than later gestational age at which delivery for PE becomes necessary; consequently, the performance of screening is superior for preterm PE than for term PE.
Strengths and limitations
The strengths of this screening study for PE in the three trimesters of pregnancy are first, examination of a large population of pregnant women attending for routine care, second, recording of data on maternal characteristics and medical history to identify known risk factors associated with PE, third, measurement of serum PAPP-A and free β-hCG by automated machines that provide reproducible results, fourth, expression of the values of serum PAPP-A and free β-hCG as MoMs after adjustment for factors that affect the measurements and fifth, use of Bayes' theorem to combine the prior risk from maternal factors with PAPP-A and free β-hCG to estimate patient-specific risks and the performance of screening for PE delivering at different stages of pregnancy.
A limitation of the study is that of optimistic bias in performance due to deriving and testing a model using the same dataset. We used five-fold cross validation to reduce such bias.
Clinical implications of the study
In a proposed new pyramid of pregnancy care 25 , assessment at 12 weeks aims to identify those at high risk of developing preterm PE and through pharmacological intervention reduce the prevalence of the disease 26, 27 . Assessment at 22 and/or 32 weeks aims to estimate the patient-specific risk of developing PE and, on the basis of such risk, define the timing and content of subsequent visits to help improve perinatal outcome.
At 11-13 weeks' gestation, serum free β-hCG is not a useful marker of PE. Serum PAPP-A improves the prediction of preterm PE provided by maternal factors alone but the improvement is small. We have reported previously that serum PAPP-A does not improve the performance provided by combined screening with maternal factors, uterine artery pulsatility index (UtA-PI), mean arterial pressure (MAP) and serum placental growth factor (PlGF), which detects 75% of preterm PE and 47% of term PE at a FPR of 10% 5 . At 19-24 weeks' gestation, serum PAPP-A is not a useful marker of PE. Serum free β-hCG improves the prediction of preterm PE provided by maternal factors alone, but the improvement is small. We have reported previously that effective screening for PE at this gestational age is provided by a combination of maternal factors, UtA-PI, MAP and PlGF, which detects 85% of preterm PE and 46% of term PE at a FPR of 10% 28 . At 30-34 weeks' gestation, combined screening by maternal factors, serum PAPP-A and free β-hCG could improve the prediction of preterm PE provided by maternal factors alone from 44% to 63%, at a FPR of 10%. However, such improvement is small by comparison with screening by a combination of maternal factors, UtA-PI, MAP, PlGF and serum soluble fms-like tyrosine kinase-1, which detects 99% of preterm PE and 66% of term PE at a FPR of 10% 29 .
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Table S1 Regression equations of serum pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-hCG) multiples of the median in pregnancies that developed pre-eclampsia Table S2 Pooled standard deviations and correlations for log 10 serum pregnancy-associated plasma protein-A (PAPP-A) and free beta human chorionic gonadotropin (β-hCG) multiples of the median in unaffected pregnancies and those that developed pre-eclampsia Table S3 Model-based and empirical areas under the receiver-operating characteristics curve (AUC) in screening for pre-eclampsia (PE) delivering < 32, < 37 and ≥ 37 weeks' gestation by maternal factors and a combination of maternal factors and serum pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-hCG) at 11-13, 19-24 and 30-34 weeks
